Oxaliplatin
- PDF / 169,935 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 18 Downloads / 170 Views
1 S
Oxaliplatin Hypersensitivity reaction, infusion reaction, severe allergic reaction and anaphylactic shock: 5 case reports
In a retrospective study of 62 patients who developed reactions to oxaliplatin reported to the National Adverse Drug Reaction Monitoring Centre, China by Peking University Cancer Hospital from January 2015 to December 2017, five patients [ages and sexes not stated] were described, who developed hypersensitivity reaction, infusion reactions or allergic reaction during treatment with oxaliplatin for malignant tumour. The patients, who had been diagnosed with malignant tumour, started receiving oxaliplatin based chemotherapy [dosages and routes not stated]. During treatment, all patients developed hypersensitivity reaction (1 patient), grade 2 infusion reactions (2 patient), severe allergic reaction (2 patients) to oxaliplatin [duration of treatments to reactions onset not stated]. Therefore, oxaliplatin was suspended in all patients resulting resolution of hypersensitivity reactions, and infusion set was replaced. Subsequently, oxaliplatin was re-started in all patients. Of these five patients, one patient, who had hypersensitivity during oxaliplatin infusion, developed hypersensitivity again and stopped the current infusion of oxaliplatin. Four patients were given oxaliplatin in subsequent chemotherapy cycles without skin test or drug desensitisation procedure. Of the two patients with previous grade 2 infusion reactions, one patient received oxaliplatin again without hypersensitivity reaction, while the other patient had anaphylactic shock on re-challenge and oxaliplatin was terminated. Of the other two patients with severe allergic reaction, one patient had the same pre-treatment plan as before, while the other patient increased the dose of glucocorticoid. Wang Y, et al. Management and outcome of hypersensitivity reactions to oxaliplatin: A real-word study in a single center. [Chinese]. Chinese Journal of Clinical Oncology 47: 729-735, No. 14, Jan 2020. Available from: URL: http://doi.org/10.3969/j.issn.1000-8179.2020.14.683 [Chinese; summarised from a translation] 803518394
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
